(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Step by step instructions to Choose the Right Auto Crash Legal counselor for Your Case - 2My skin feels drier, my lips thinner and my makeup heavier. How do I adjust my routine for aging skin?
- 3Instructions to Pick the Right Senior Protection Plan.
- 4Distributed storage Answers for Information Reinforcement
- 5She's been a Bond girl and a mutant. Now she's grappling with Hollywood's obsession with 'eternal youth.'
- Living Abroad: Social Inundation and Self-improvement
- Instructions to Augment the Presentation of Your Kona SUV
- Building a Flourishing Business: Illustrations from Business people
- Ergonomic Office Seats for Work spaces
- Best Exciting ride: Which One Rushes You the Most?
- Help Your Business with Master Web based Promoting Arrangements
- More people are addicted to marijuana, but fewer of them are seeking help, experts say
- Individual Preparation Administrations to Raise Your Wellness Process
- 4 African Vacationer Locations
